[go: up one dir, main page]

WO2007142231A1 - Agent destiné à améliorer la fluidité du sang - Google Patents

Agent destiné à améliorer la fluidité du sang Download PDF

Info

Publication number
WO2007142231A1
WO2007142231A1 PCT/JP2007/061364 JP2007061364W WO2007142231A1 WO 2007142231 A1 WO2007142231 A1 WO 2007142231A1 JP 2007061364 W JP2007061364 W JP 2007061364W WO 2007142231 A1 WO2007142231 A1 WO 2007142231A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
mol
fluidity
amino acid
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/061364
Other languages
English (en)
Japanese (ja)
Inventor
Hiroyuki Arita
Masato Saito
Hiroshi Echizen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Dairies Corp
Original Assignee
Meiji Dairies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corp filed Critical Meiji Dairies Corp
Priority to JP2008520586A priority Critical patent/JP5764281B2/ja
Publication of WO2007142231A1 publication Critical patent/WO2007142231A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a composition for improving blood fluidity (blood rheology).
  • the present invention relates to a technical field such as a blood disease preventive agent and a thrombosis preventive agent by increasing blood fluidity.
  • Blood can be differentiated from blood cell components such as red blood cells, white blood cells, and platelets, and plasma components that contain various proteins, lipids, and minerals. Blood fluidity, in other words, blood viscosity, is thought to be particularly affected by red blood cell volume and deformability (ability to deform and pass through narrow spaces), plasma fibrinogen, white blood cells, and platelets. ing.
  • MC-FAN Micro Channel array Flow Analyzer
  • Non-patent Document 4 It has been researched and developed for compounds and Z or compositions that affect blood fluidity. For example, it has been reported that when a fruit acid supplement is ingested during long-distance running, an increase in blood viscosity is suppressed when it is further run (Non-patent Document 4).
  • Patent Document 1 includes L-glutamine 8 to 27 parts by mass, L-arginine 6 to 21 parts by mass, L-leucine 8 to 25 parts by mass, L-isoleucine 6 to 20 parts by mass, and L-parin.
  • Contains 6-19 parts by weight of 5 amino acids as essential components (L-glutamine 0.34g, L-arginine 0.34g, L-mouth isine 0.28g, L-isoleucine 0.18g, L-parin 0.18g, L- (Containing lysine 0.14g, L-methionine 0.12g, L-threonine 0.18g, L-histidine 0.10g, L-proline 0.10g, L-ferulanine 0.01g, L-tributophane 0.03g) It is described that the blood fluidity was improved when the food was ingested 3 times a day, 1 bag after each meal (3.96 g as the five essential amino acids), taking a period of 10 weeks. .
  • Patent Document 1 JP 2005-272410 A
  • Non-Patent Document 1 BRAIN Techno-Youth, No. 86, Jul 15, 2001
  • Non-Patent Document 2 Microvasc. Res. 44: 226-240, 1992
  • Non-Patent Document 3 Microvasc. Res. Jan; 47 (1): 126-39, 1994
  • Non-Patent Document 4 Journal of Japan Society for Molecular Science, 2003, Vol. 6, No. 2, pp. 83-88
  • Non-Patent Document 5 Journal of Japanese Society for Molecular Science, 2004, Vol. 7, No. 1, No. 1, 25-31 Disclosure of Invention
  • the prior art is a technique for improving blood fluidity under special conditions, such as V, where the athlete runs long distances, and the force is often a drug that lowers blood viscosity. The effect has not been confirmed until long-term use of the compound.
  • An object of the present invention is to develop a blood viscosity reducing agent that is effective immediately in normal life in healthy individuals other than athletes.
  • the invention of the present application is expected to increase in the future along with the aging of society, by using inexpensive and highly safe amino acids that are commonly used for normal eating and drinking in a specific composition. It has an excellent effect that it is useful for the treatment and Z or prevention of diseases associated with decreased blood flow fluidity such as thrombosis and hypertension.
  • FIG. 1 An outline of the experimental method, showing the relationship between the intake time of amino acids and the first and second blood sampling time points.
  • FIG. 2 Influence on blood flow by drinking VAAM (amino acid beverage) (190g). The same number indicates the same subject.
  • FIG. 4 Effect of VAAM Mix. Ingestion (amino acid weight 3g) on blood flow of 6 subjects.
  • the blood flow time was shortened to 42.8 ⁇ 1.8 (seconds) (mean person S.D.) after force intake; 45.0 ⁇ 1.9 (seconds) before intake.
  • FIG. 6 Effects of BCAA drinking (amino acid weight 3g) on blood flow of 6 subjects.
  • the blood flow time was 41.1 ⁇ 2.7 (seconds) before ingestion; after force ingestion; 39.8 ⁇ 2.4 (seconds) (mean person S.D.).
  • FIG. 8 Effects on the blood flow of each of 6 subjects by drinking CAAM (amino acid weight 3g).
  • Blood viscosity is considered to be a risk factor for cardiovascular disease.
  • blood pressure increases to maintain blood flow to the tissue.
  • the shear rate decreases and the blood viscosity decreases. Increased blood flow is further reduced.
  • This circulatory disorder caused by an increase in blood viscosity is called hyperviscosity syndrome, and it often happens to lie on the bottom of various diseases! (Nippon Physiology Magazine, Vol. 66, pp.234-244).
  • the food and drink containing the blood flow improving agent or blood viscosity reducing agent and the blood fluidity improving agent or blood viscosity reducing agent of the present invention is a cardiovascular system including hypertension and thrombosis, shoulder stiffness, cooling.
  • Peripheral or central blood circulation disorders such as sex, infarction, fatigue, hyperlipidemia, arteriosclerosis-Diseases caused by blood flow disorders can be prevented and / or treated by improving blood flow fluidity .
  • the blood fluidity can be measured using, for example, a liquid fluidity measurement device (MC-FAN: Micro Channel Array Flow Analyzer, Emshi Laboratory Inc.).
  • M-FAN Micro Channel Array Flow Analyzer, Emshi Laboratory Inc.
  • This device allows the flow of cells flowing through a channel by flowing blood into a channel (microchannel array) formed by crimping a glass substrate with fine grooves on a silicon chip processed using semiconductor microfabrication technology. The state is directly observed and recorded with a microscope (the company's website).
  • blood viscosity is a risk factor for various diseases such as cardiovascular diseases, and so for the treatment and Z or prevention of these diseases, including cardiovascular diseases that have been increasing in recent years. It is useful to develop a composition that reduces blood viscosity or improves blood fluidity. Factors that increase blood viscosity include decreased red blood cell shape deformability and red blood cell aggregation. For example, the accumulation of Ca in erythrocytes and the resulting changes in membrane protein interactions are said to contribute to essential hypertension. On the other hand, as a factor that lowers blood viscosity, for example, it is said that NO-generating substances increase red blood cell deformability (Nippon Physiology Magazine, Vol. 66, No. 9, pp.287-297). As described above, it has been reported that the ingestion of fruit acid and black vinegar reduces the blood viscosity of athletes during sports.
  • the present invention includes a blood fluidity improving agent comprising an amino acid composition containing threonine, proline, glycine, norine, isoleucine, leucine, tyrosin, phenylalanine, lysine, methionine, tryptophan, histidine and arginine as an active ingredient.
  • blood viscosity Includes a reducing agent.
  • the present invention includes threonine, proline, glycine, norine, isoleucine, leucine, tyrosine, phenylalanin, lysine, methionine, tryptophan, histidine and arginine, aspartic acid, serine, glutamic acid and Includes a blood fluidity improving agent or blood viscosity reducing agent containing an amino acid composition containing alanine as an active ingredient
  • an amino acid composition comprising threonine, proline, glycine, parin, isoleucine, leucine, tyrosine, phenylalanin, lysine, methionine, tryptophan, histidine and arginine as an active ingredient. It contains a blood fluidity improving agent or a blood viscosity reducing agent.
  • the present invention specifically includes threonine, proline, glycine, parin, isoleucine, leucine, tyrosine, phenylalanine, lysine, methionine, tryptophan, histidine, arginine, aspartic acid, serine, It includes a blood fluidity improving agent or a blood viscosity reducing agent containing glutamic acid and an amino acid composition having an alanine strength as active ingredients.
  • Each amino acid constituting the amino acid composition of the present invention may be a free amino acid or a pharmaceutically or food acceptable salt.
  • each amino acid may be hydrochloride, lactate, or the like.
  • amino composition of the present application examples include the following.
  • an amino acid composition that also has threonine, proline, glycine, parin, iso-orcinine, leucine, tyrosine, phenylalanine, lysine, methionine, tryptophan, histidine, and arginine as an active ingredient
  • amino acids by weight, 2-15 mol of threonion, 4-30 mol of proline, 7-20 mol of glycine, 4-8 mol of Norin, 3-9 mol of iso-Icin, 2-12 of leucine Moles, 1-9 moles of tyrosine, and phenylalanin
  • a blood fluidity improving agent or blood viscosity reducing agent characterized by containing 0.5 to 5 mol, lysine in a proportion of 5 to 11 mol, and containing methionine, tryptophan, histidine, and arginine in a proportion of 5 mol or less, respectively. Is included.
  • Amino acid composition comprising threonine, proline, glycine, norine, isoleucine, leucine, tyrosine, phenenolealanine, lysine, methionine, tryptophan, histidine, anoleginine, aspartic acid, serine, glutamic acid, and alanine Is a blood fluidity improving agent or blood viscosity reducing agent.
  • the amino acids are in a weight ratio of 2 to 15 mol of threonion, 4 to 30 mol of proline, 7 to 20 mol of glycine, 4 to 8 mol of Norin, and 3 to 9 mol of isoleucine.
  • the present invention includes 6.92% by weight of threonion, 16.79% by weight of proline, 11.60% by weight of glycine, 5.56% by weight of phosphorus, 4.79% by weight of isoleucine, and 6.53% by weight of leucine.
  • Hue - Ruaranin is 5.12 wt%, 12.75% by weight lysine and lysine hydrochloride, Mechionin 0.64 wt%, tryptophan 3.63% by weight, histidine 3.23 weight 0/0, arginine 4.96 weight 0/0, 0.22 wt% Asuparagin acid as Asuparagin acid Na, serine 2.11 weight%, glutamic acid 3.81% by weight, and Aranin blood flow improvers as an active ingredient an amino acid composition consisting of 4.41 wt% or Contains a blood viscosity reducing agent.
  • the usage form of the amino acid composition of the present invention is not particularly limited, it can be used for medical purposes, for drinking, and for nutritional supplements.
  • composition for medical use, it can be used by a general administration route such as oral administration, rectal administration, injection, administration by infusion.
  • oral administration the composition itself or the drug It can be mixed with academically acceptable carriers, excipients, diluents, etc. to form powders, granules, tablets, capsules, troches, syrups and the like.
  • an appropriate buffer, an isotonic agent, etc. may be added and dissolved in sterile distilled water.
  • composition of the present invention is extremely safe, its dosage can be set in a very wide range, and further varies depending on the administration method and purpose of use, but usually 0.5 to 5 g at a time, daily dosage. 1 to 20 g, preferably 5 to 10 g.
  • 10 to 1000 ml as a 0.5 to 10 wt% solution, preferably 100 to 400 ml as a 1 to 4 wt% solution may be used as a single dose.
  • the amino acid composition of the present application can be edible as it is, but can also be used as an additive to various foods.
  • the composition of the present invention can be dissolved in water to make a beverage.
  • other nutritional components such as aqueous vitamins and taurine can be further added.
  • a salt such as sodium salt sodium, acids such as taenoic acid and Z or other suitable flavors to make a beverage.
  • a pH adjusting agent and a chelating agent can be further added.
  • Amino acid beverage (VAAM, 190 g, Meiji Dairies) was used as a sample, and water (190 g) was used as a placebo.
  • AspNa-H 0 is 7 mg
  • Thr is 207 mg
  • Blood was collected by adding 0.25 ml of heparin (5% of the whole blood) to a vacuum blood collection tube in advance and collecting 5 ml from the subject. The obtained fresh blood is immediately used as a measurement sample. Using. MC-FAN (Micro Channel Array Flow Analyzer) was used for the measurement. In MC-FAN, a pressure of 20 cm water column was applied to the flow path system, and the flow rate of 100 ⁇ 1 of whole blood was measured under this constant pressure. The variation at each measurement was corrected by measuring the flow rate of physiological saline 100 1 at each measurement.
  • MC-FAN Micro Channel Array Flow Analyzer
  • VAAM amino acid beverage
  • VAAM M ix Includes Asp 7 mg, Thr force S207 mg, Ser 63 mg, Glu 114 mg, Gly 347 mg ⁇ Ala 132 mg, Val 166 mg, Met 19 mg, lie 143 mg, Leu 196 mg, Contains Tyr 208 mg, Phe 153 mg, Trp 109 mg, LysHCl 382 mg, His 97 mg, Arg 149 mg, and Pro S503 mg. This was wrapped in oblate (manufactured by Biptoukiyo Co., Ltd.) and drunk by 6 subjects with 50 g of soft water. Table 1 shows the composition (% by weight) of VAAM Mix.
  • the sample was drunk immediately after blood collection, and blood was collected again after 1 hour. During this one hour, the subject was at rest.
  • the blood passage time before and after drinking the sample was measured and compared to confirm the blood flow improvement effect. In addition, Each blood sample was measured twice.
  • Blood was collected by adding 0.25 ml of heparin (5% of the whole blood) in advance to a vacuum blood collection tube, and collecting 5 ml from the subject. The obtained fresh blood was immediately used as a measurement sample.
  • MC-FAN Micro Channel Array Flow Analyzer
  • a pressure of 20 cm water column was applied to the channel system, and the flow rate of 100 ⁇ 1 of whole blood was measured under this constant pressure. Variation at each measurement was corrected by measuring the flow rate of physiological saline 100 1 at each measurement.
  • BCAA and CAAM amino acids
  • Samples were wrapped in oblate (manufactured by Biptoukiyo Co., Ltd.) and drunk by 6 subjects with 50 g of soft water.
  • BCAA Norin was 750 mg
  • Leucine was 1500 mg
  • Isoleucine was 750 mg.
  • Yarn ⁇ (wt 0/0) of CAAM are shown in Table 2.
  • Blood was collected once before drinking the sample.
  • the sample was drunk immediately after blood collection, and blood was collected again after 1 hour. During this one hour, the subject was at rest.
  • the blood flow improvement time before and after drinking was measured and compared to confirm the blood flow improvement effect.
  • Blood was collected by previously adding 0.25 ml of heparin (5% of the whole blood) to a vacuum blood collection tube, and collecting 5 ml from the subject. The obtained fresh blood was immediately used as a measurement sample.
  • the present invention can be used in the fields of foods, beverages, dietary supplements and medicine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le développement d'un agent destiné à réduire une viscosité du sang, l'agent pouvant agir rapidement chez une personne normale ayant un rythme de vie quotidien normal. L'invention concerne un agent destiné à améliorer une fluidité du sang ou à réduire une viscosité du sang, l'agent contenant une composition d'acides aminés spécifique, susceptible d'être ingérée par voie orale. L'invention concerne également une boisson ou un aliment contenant l'agent.
PCT/JP2007/061364 2006-06-08 2007-06-05 Agent destiné à améliorer la fluidité du sang Ceased WO2007142231A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008520586A JP5764281B2 (ja) 2006-06-08 2007-06-05 血液流動性改善剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-159901 2006-06-08
JP2006159901 2006-06-08

Publications (1)

Publication Number Publication Date
WO2007142231A1 true WO2007142231A1 (fr) 2007-12-13

Family

ID=38801482

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/061364 Ceased WO2007142231A1 (fr) 2006-06-08 2007-06-05 Agent destiné à améliorer la fluidité du sang

Country Status (2)

Country Link
JP (1) JP5764281B2 (fr)
WO (1) WO2007142231A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010041647A1 (ja) * 2008-10-06 2012-03-08 株式会社明治 アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤
JP2019112470A (ja) * 2019-04-19 2019-07-11 株式会社東洋新薬 血流改善剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0624977A (ja) * 1992-07-10 1994-02-01 Rikagaku Kenkyusho 抗肥満剤及び抗高脂血症剤
JP2518692B2 (ja) * 1989-06-14 1996-07-24 理化学研究所 筋力持続剤，滋養強壮剤，輸液用剤，栄養補給剤，疲労回復剤及び乳酸生成調節剤
JP2003128560A (ja) * 2001-10-23 2003-05-08 Kikkoman Corp 血液流動性改善剤
JP2004123707A (ja) * 2002-07-29 2004-04-22 Toyo Shinyaku:Kk 血流改善組成物
JP2005272410A (ja) * 2004-03-26 2005-10-06 Ajinomoto Co Inc 抗動脈硬化用及び／又は血液レオロジー改善用経口アミノ酸組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2518692B2 (ja) * 1989-06-14 1996-07-24 理化学研究所 筋力持続剤，滋養強壮剤，輸液用剤，栄養補給剤，疲労回復剤及び乳酸生成調節剤
JPH0624977A (ja) * 1992-07-10 1994-02-01 Rikagaku Kenkyusho 抗肥満剤及び抗高脂血症剤
JP2003128560A (ja) * 2001-10-23 2003-05-08 Kikkoman Corp 血液流動性改善剤
JP2004123707A (ja) * 2002-07-29 2004-04-22 Toyo Shinyaku:Kk 血流改善組成物
JP2005272410A (ja) * 2004-03-26 2005-10-06 Ajinomoto Co Inc 抗動脈硬化用及び／又は血液レオロジー改善用経口アミノ酸組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WALTER R. ET AL.: "Pharmacological Concentrations of Arginine Influence Human Whole Blood Viscosity Independent of Nitric Oxide Synthase Activity in Vitro", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 269, 2000, pages 687 - 691, XP003019787 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010041647A1 (ja) * 2008-10-06 2012-03-08 株式会社明治 アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤
JP2019112470A (ja) * 2019-04-19 2019-07-11 株式会社東洋新薬 血流改善剤

Also Published As

Publication number Publication date
JPWO2007142231A1 (ja) 2009-10-29
JP5764281B2 (ja) 2015-08-19

Similar Documents

Publication Publication Date Title
TW201827068A (zh) 胺基酸組合物及肌肉疾病與病症之治療方法
Ishida et al. Effect of an excess intake of casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro in subjects with normal blood pressure, high-normal blood pressure, or mild hypertension
JPH0624977A (ja) 抗肥満剤及び抗高脂血症剤
IL286592B2 (en) Amino acid compounds for the treatment of liver disease
CN102170876A (zh) 含有氨基酸组合物作为有效成分的耐力提高剂、抗疲劳剂或疲劳恢复剂
CA2969010C (fr) Utilisation d'une composition contenant du chelate d'acide amine de fer (ii) dans la preparation d'un medicament destine a reguler et a controler le metabolisme des graisses
JP5939550B2 (ja) 酸化型アルブミン低下剤
WO1997025060A1 (fr) Compositions d'acides amines
WO2009149196A1 (fr) Formulations à enrobage entérique de polyéthylèneglycol et d’un ou plusieurs acides aminés solubles pour ingestion orale et leur assimilation améliorée
EP1552826A1 (fr) Compositions d'acides amines destinees a ameliorer les fonctions centrales
WO2007142231A1 (fr) Agent destiné à améliorer la fluidité du sang
JP2002003372A (ja) 造血および栄養状態改善用アミノ酸組成物
Wulandari et al. Systematic review of branched-chain amino acid supplementation high in leucine on interleukin-6
US20150202181A1 (en) Method of and compounds for the reduction of alcoholic hangover
EP2496232B1 (fr) Procede pour ameliorer l'endurance
WO2002074303A1 (fr) Compositions d'acides amines pour ameliorer l'insuffisance renale
JP6423717B2 (ja) 非糖質性エネルギー産生増強剤
JPH07285859A (ja) 鎮痛作用増強剤
HK1075608A (en) Amino acid compositions for improving central functions
KR20040071350A (ko) 지구성 운동시 피로억제 및 운동 수행 후 면역기능 향상을위한 약학적 조성물 또는 기능성 식품
JP2012144567A (ja) 分岐鎖アミノ酸の心不全適応

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07744716

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008520586

Country of ref document: JP

122 Ep: pct application non-entry in european phase

Ref document number: 07744716

Country of ref document: EP

Kind code of ref document: A1